

CLEARBRIDGE HEALTH LIMITED
(Company Registration No. 201001436C)
(the "**Company**")

**PROPOSED ACQUISITION OF SHARES IN PT INDO GENESIS MEDIKA – SUPPLEMENTAL
DEED TO THE REDEEMABLE EXCHANGEABLE BOND**

Unless otherwise defined herein or the context otherwise requires, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Company's announcements dated 23 August 2018, 13 November 2018, 3 April 2019, 8 April 2019, 7 May 2019 and 24 June 2019 in relation to the Proposed Transactions.

The Board refers to the announcements dated 3 April 2019 and 24 June 2019 in relation to the redeemable exchangeable bond subscription agreement entered into between SAM Laboratory Pte. Ltd. ("**SAM**") and PT Kreasi Putra Nusantara ("**KPN**") on 3 April 2019 (as amended and supplemented by the supplemental deed dated 24 June 2019) ("**REBSA**"). Under the REBSA, the REB is exchangeable at the option of SAM into shares of the Target held by KPN, representing 20% of the issued and paid up capital of the Target, subject to KPN's option to redeem the REB at any time within one (1) year from the completion date of the REBSA (the "**Redemption Period**").

In light of the COVID-19 pandemic, SAM and KPN have entered into a second supplemental deed to extend the Redemption Period for an additional twelve (12) months i.e. within twenty-four (24) months from the completion date of the REBSA. Accordingly, the Redemption Period has been extended to 23 June 2021. Other terms and conditions of the REBSA remain unchanged.

A copy of the second supplemental deed is available for inspection from 9.00 a.m. to 5.30 p.m.¹ at the registered address of the Company for a period of three (3) months from the date of this announcement.

The Company will make further announcements as and when there are further material updates and developments in respect of the Proposed Transactions.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Chief Executive Officer and Executive Director

22 June 2020

¹ Prior appointment with the Company is required. Please contact the Company's Investor Relations team at +65 6251 0136 or email: contactus@clearbridgehealth.com

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*